Lichen sclerosus is a skin disease that affects the genital and anal areas. In some cases, they may appear on upper body such as arms and breast regions. The main cause of lichen sclerosus is still unknown, but some of the other causes are hormonal imbalance, hyper immunity reactions. Patients with skin destruction around genital or anal region are more susceptible to develop lichen sclerosus. Generally women suffering from vulva’s lichen sclerosus are at a high risk of developing vulvar cancer.
Increasing prevalence of skin diseases worldwide is one of the major factors contributing to the growth of the market. Moreover, hormonal misbalance in females undergoing menopause are more susceptible to lichen sclerosus, which boosts the growth of market.
On the other hand, availability of exact treatment, and unawareness about rare skin diseases among people may hamper the market growth.
The lichen sclerosus treatment market is expected to grow at a CAGR of 7.8% during the forecast period and is estimated to reach USD 150 million by 2023.
FIGURE 1 Lichen Sclerosus Treatment Global Market by mode of administration, 2016 (%)
Key Players in the Global Lichen Sclerosus Treatment Market
Some of the key players in this lichen sclerosus treatment market are AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sandoz AG (Novartis AG), Sanofi S.A., Valeant Pharmaceuticals, and Zylera Pharmaceuticals.
Lichen Sclerosus Treatment Market Segments The global sclerosus treatment market is segmented on the basis of type of treatment, which includes drug therapy and surgery. The drug therapy is further segmented into corticosteroid, immune modulating drugs, retinoid like agents, and others. Surgery is further segmented into laser surgery, circumcision, and others.
On the basis of mode of administration, the lichen sclerosus treatment market is segmented into oral, topical, IV (Intravenous), and others. Oral is further segmented into tablets, capsule, and others. The topical administration is further segmented into creams, ointment, and others.
On the basis of end user, the lichen sclerosus treatment market is segmented into hospitals, dermatology clinics, pharmacies, and others.
Regional Analysis of the Global Lichen Sclerosus Treatment Market
The American region accounted for the largest share of the global lichen sclerosus treatment market due to increasing prevalence of skin disease and demand for new topical products for its treatment. According to the American Osteopathic College of Dermatology, in 2013, USD 75 billion were spent on skin disease by the Americans. Aging population is another factor responsible for the market growth in the American countries.
Europe is the second largest market that holds a noticeable share of the global lichen sclerosus treatment market owing to an increasing awareness regarding skin diseases, demand for skin care cosmetics, and growing market for dermatology in many European countries.
In Asia Pacific, increasing number of dermatology clinics, rising demand for evidence based skin care, and increasing prevalence of skin diseases drives the growth of the lichen sclerosus treatment market.
The Middle East & Africa is expected to show a steady but positive growth in this market due constant demand for diagnostics services in dermatology.
The report on the global lichen sclerosus treatment market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain deeper insight to the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions
|Market Size||USD 150 million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer Inc., Sandoz AG (Novartis AG), Sanofi S.A., Valeant Pharmaceuticals, and Zylera Pharmaceuticals.|
|Key Market Opportunities||
|Key Market Drivers||
Frequently Asked Questions (FAQ) :
Lichen Sclerosus Treatment Market is projected to grow at approximately 7.8% CAGR during the assessment period (2017-2023).
Lichen Sclerosus Treatment Market is estimated to reach a valuation of approx. USD 150 MN by the end of 2023.
Increasing prevalence of skin diseases and the rising per capita healthcare expenditure, are major tailwinds pushing the growth of the global Lichen Sclerosus Treatment Market.
North America holds the largest share in the Global Lichen Sclerosus Treatment Market, followed by Europe and the Asia Pacific, respectively.
AstraZeneca plc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Pfizer Inc., Merck & Co., Inc., Sandoz AG (Novartis AG), Valeant Pharmaceuticals, Sanofi S.A., and Zylera Pharmaceuticals, are some of the top players operating in the Global Lichen Sclerosus Treatment Market.